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Abstract
Objective—Lactate is an intermediate of glucose metabolism that has been implicated in the 
pathogenesis of insulin resistance. This study evaluated the relationship between glucose kinetics 
and plasma lactate concentration ([LAC]) before and after manipulating insulin sensitivity by 
progressive weight loss.
Methods—Forty people with obesity (BMI=37.9±4.3 kg/m2) were randomized to weight 
maintenance (n=14) or weight loss (n=19). Subjects were studied before and after 6 months of 
weight maintenance and before and after 5%, 11% and 16% weight loss. A hyperinsulinemic-
euglycemic clamp procedure in conjunction with [6,6-2H2]glucose tracer infusion was used to 
assess glucose kinetics.
Results—At baseline, fasting [LAC] correlated positively with endogenous glucose production 
rate (r=0.532, p=0.001) and negatively with insulin sensitivity, assessed as the insulin-stimulated 
glucose disposal (r=−0.361, p=0.04). Progressive (5% through 16%) weight loss caused a 
progressive decrease in fasting [LAC], and the decrease in fasting [LAC] after 5% weight loss was 
correlated with the decrease in endogenous glucose production (r=0.654, p=0.002) and the 
increase in insulin sensitivity (r=−0.595, p=0.007).
Conclusion—This study demonstrates the inter-relationships among weight loss, hepatic and 
muscle glucose kinetics, insulin sensitivity, and [LAC], and suggests that [LAC] can serve as an 
additional biomarker of glucose-related insulin resistance.
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INTRODUCTION
The use of plasma glucose as fuel involves its transport into cells where it is metabolized to 
pyruvate in the cytosol before entry into the mitochondria for complete oxidation in the 
tricarboxylic acid cycle. Pyruvate that does not enter the mitochondria is converted to lactic 
acid, which rapidly dissociates to lactate and hydrogen. Therefore, lactate is a product of 
incomplete glucose metabolism. During resting conditions, plasma lactate concentration 
([LAC]) increases when flux through glycolysis exceeds the rate of mitochondrial oxidation. 
Accordingly, an increase in [LAC] could be an indicator of impaired glucose metabolism. In 
fact, fasting [LAC] is higher in people with obesity (1, 2) and type 2 diabetes (3, 4, 5) than in 
healthy lean people. An increase in [LAC] can also influence glucose metabolism by 
providing a gluconeogenic precursor to the liver and by disrupting muscle insulin signaling 
and insulin-mediated muscle glucose uptake (6, 7, 8, 9). Therefore, an increase in [LAC] can 
be both a biomarker and a cause of impaired glucose metabolism.
Weight loss improves multi-organ insulin sensitivity and insulin-mediated glucose 
metabolism in people with obesity (10). The therapeutic effect of weight loss on glucose 
metabolism suggests weight loss should decrease fasting [LAC], which could contribute to 
the beneficial effect of weight loss on metabolic function. However, the effect of weight loss 
on lactate metabolism is not clear because of conflicting results among studies. Weight loss 
has been shown to decrease fasting [LAC] in people with obesity and metabolic syndrome 
(2), but not in metabolically healthy people with obesity or people with obesity and type 2 
diabetes (11, 12). The reason(s) for the inconsistency among studies is not clear, but could 
be related to differences in sample size and health status of the participants.
The purpose of this study was to evaluate the relationship between glucose kinetics and 
[LAC], and determine whether weight loss-induced changes in insulin sensitivity and 
endogenous glucose production are associated with changes in lactate metabolism. To this 
end, we evaluated [LAC] and glucose kinetics during basal conditions and during glucose 
and insulin infusion before and after progressive (5%, 11% and 16%) weight loss in people 
with obesity.
METHODS
Subjects
Forty men and women (BMI=37.9 ± 4.3 kg/m2, 44 ± 12 years old) were enrolled in this 
study. The assessment of lactate metabolism was made while subjects participated in a study 
that involved evaluating insulin sensitivity during progressive weight loss, conducted from 
January 2011 until October 2015 (10). No subject had diabetes or other serious illnesses, 
were taking medications known to interfere with insulin action or lactate metabolism, or 
consumed excessive alcohol (>21 drinks/week for men and >14 drinks/week for women). 
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Written informed consent was obtained from all subjects before their participation in this 
study, which was approved by the Institutional Review Board of Washington University 
School of Medicine in St. Louis, MO.
Study protocol
Subjects were randomly assigned to weight maintenance (n=14 [5 withdrew after being 
informed of their randomization and 1 dropped out], 11 women and 3 men) or diet-induced 
weight loss (n=19 [1 dropped out], 16 women and 3 men) using a computerized 
randomization list provided by the statistician of the study (Figure 1). The characteristics of 
each group have been previously reported (10). Subjects in the weight loss group attended 
weekly individual behavior education sessions and dietary counseling sessions, and were 
prescribed a low-calorie diet (50-55% of energy as carbohydrate, 30% of energy as fat, and 
15-20% of energy as protein) of self-prepared foods to achieve 5% weight loss. After 5% 
weight loss was achieved, solid and liquid meal replacements were provided as needed to 
achieve the 10% and 15% weight loss targets. All subjects in the weight loss group were 
studied before and after 5% loss; 9 subjects continued to lose weight and were studied again 
after ~11% and ~16% weight loss. After subjects achieved each weight loss target, a weight 
maintenance diet was prescribed to maintain a stable body weight (<2% change) for at least 
3 weeks before repeat testing was performed to avoid the potential effect of energy 
imbalance on our outcome measures. Subjects in the weight loss group were studied before 
and after a median (quartiles) of 3.5 (2.9, 4.6), 6.8 (6.0, 8.6) and 10.4 (9.6, 10.4) months for 
5%, 11% and 16% weight loss, respectively. Subjects randomized to weight maintenance 
were studied at baseline and after 6 months.
Body fat mass and fat-free mass were determined by using dual-energy X-ray 
absorptiometry (13). A hyperinsulinemic-euglycemic clamp procedure, in conjunction with 
[6,6-2H2]glucose tracer infusion, was used to assess glucose kinetics during basal and 
insulin-stimulated conditions (10). The rate of insulin infusion (50 mU/m2 body surface 
area/min) was designed to achieve typical postprandial plasma insulin concentrations (14). 
Blood samples were obtained from an indwelling radial arterial catheter.
Sample analyses and calculation of glucose kinetics
[LAC] was measured on a Beckman DxC600 autoanalyzer, using reagents also from 
Beckman (Brea, CA) (15). Plasma glucose tracer-to-tracee ratio (TTR) was determined by 
using gas chromatography-mass spectroscopy (16). Glucose rate of appearance (Ra) in 
plasma during basal conditions provides an index of hepatic glucose production rate, and 
was calculated by dividing the glucose tracer infusion rate by the average plasma glucose 
TTR during the last 30 min of the basal period. During the clamp procedure, glucose rate of 
disappearance (Rd) from plasma provides an index of insulin-stimulated muscle glucose 
uptake, and was calculated as the sum of endogenous glucose Ra and the rate of infused 
(exogenous) glucose. Insulin sensitivity was determined as the relative increase in glucose 
Rd during insulin infusion.
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Statistical Analysis
A two-way repeated measures ANOVA with group (weight loss versus maintenance) and 
time (pre-versus post-intervention) as factors was used to evaluate the effects of 5% weight 
loss on [LAC]; and significant interactions were followed by Tukey’s post hoc procedure. A 
one-way repeated measures ANOVA was used to assess the effect of progressive weight loss 
on [LAC]. Effects of time were followed by simple contrasts to assess differences from 
baseline and trend analysis to assess the linear, quadratic, and cubic components of the 
overall time-related change. Pearson’s correlation was used to evaluate the relationship 
between [LAC] and glucose kinetics. Results are shown as means ± SD. A P-value of 0.05 
or less was considered statistically significant. The sample size was based on the primary 
outcome of the original study (change in insulin sensitivity during weight loss) as reported 
previously (10). Statistical analyses were performed by using SPSS (version 24, IBM, 
Armonk, NY).
RESULTS
Inter-relationships among [LAC], glucose production rate, and insulin sensitivity
At baseline, there was a three-fold range in [LAC] from 0.6 mmol/L to 1.9 mmol/L. 
However, fasting [LAC] correlated positively with glucose Ra (Figure 2A) and negatively 
with skeletal muscle insulin sensitivity, assessed as the relative increase in glucose Rd during 
insulin infusion (Figure 2B). Insulin infusion had a variable effect on [LAC], which ranged 
from a 76% decrease to a 100% increase; the insulin-induced change in [LAC] was 
positively correlated with the insulin-stimulated increase in glucose Rd (Figure 2C). The 
relationship between fasting [LAC] and glucose Rd during clamp or the absolute increase in 
glucose Rd during insulin infusion was not statistically significant (r=−217, p= 0.225 and r=
−266, p= 0.134, respectively).
Effects of weight loss on lactate and glucose metabolism
Compared with subjects randomized to weight maintenance, 5% weight loss caused a 
decrease in fasting [LAC] (Figure 3A) and an increase in the relative change in [LAC] 
induced during insulin infusion (Figure 3B). The relative decrease in fasting [LAC] after 5% 
weight loss correlated with both the relative decrease in basal glucose Ra (Figure 3C) and 
the relative increase in insulin sensitivity (assessed as a relative increase in glucose Rd 
during a hyperinsulinemic-euglycemic clamp procedure) (Figure 3D). Progressive 5% to 
16% weight loss caused a progressive decline in fasting [LAC] (Figure 4A) and a 
progressive increase in the relative change in [LAC] induced by insulin infusion (Figure 4B), 
in conjunction with a progressive increase in muscle insulin sensitivity reported previously 
(10).
DISCUSSION
In this study, we evaluated the relationship between [LAC] and glucose kinetics and the 
effect of weight loss on lactate metabolism in people with obesity. We found fasting [LAC] 
was positively correlated with the rate of endogenous glucose production, but negatively 
correlated with insulin sensitivity, assessed as the relative increase in glucose Rd during the 
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clamp procedure. To further investigate the relationship between [LAC] and insulin action, 
we assessed [LAC] in a subset of participants after weight loss-induced manipulation of 
insulin sensitivity. Progressive weight loss (5% through 16%) caused a progressive decrease 
in fasting [LAC], and the change in fasting [LAC] after 5% weight loss was directly 
correlated with a relative decrease in basal glucose Ra and relative increase in insulin-
sensitivity. These data support the inter-relationship between hepatic and skeletal muscle 
glucose metabolism and [LAC], and suggest fasting [LAC] is a biomarker of glucose-related 
insulin resistance.
Our finding that fasting [LAC] is associated with insulin resistance is consistent with data 
from previous studies that have shown fasting [LAC] is higher in people with obesity and 
those with type 2 diabetes than in people who are lean and healthy (4, 5, 17, 18, 19). The 
design of our study is not able to determine the precise mechanism(s) responsible for the 
observed correlation between fasting [LAC] and insulin sensitivity and the progressive 
decline in fasting [LAC] with progressive weight loss. There is no storage depot for lactate, 
so circulating lactate represents a balance between production and plasma clearance. During 
postabsorptive, resting conditions, skeletal muscle (20) and adipose tissue (1, 21) are major 
sources of whole-body lactate production, whereas the splanchnic bed (liver and gut) is 
likely an important source of postprandial lactate production (22). Circulating lactate can be 
excreted by the kidneys or taken up by specific tissues and converted to glucose (primarily 
by liver and kidneys) (9, 23), or oxidized for fuel (primarily by heart and skeletal muscle) 
(24, 25). Presumably, during basal conditions, the weight loss-induced increase in insulin 
sensitivity and decrease in endogenous glucose production caused a decrease in the delivery 
of glucose to skeletal muscle and adipose tissue and increased the proportion of muscle and 
adipose tissue glucose uptake that was completely oxidized or converted to glycogen, 
thereby decreasing whole-body lactate production and fasting [LAC].
In contrast with the relationship between [LAC] and insulin sensitivity during postabsorptive 
conditions, [LAC] in response to either glucose ingestion or glucose infusion is lower in 
people who have insulin-resistant glucose metabolism than in those who are insulin sensitive 
(18, 26, 27, 28). The precise mechanism explaining this observation is not known, but it is 
likely that the impairment in tissue glucose uptake associated with insulin resistance limits 
the availability of glucose for metabolism to lactate (1, 5, 29, 30, 31), whereas the increase 
in tissue glucose uptake associated with insulin sensitivity increases glycolytic flux and 
lactate production. In our subjects, the relative change in [LAC] during the 
hyperinsulinemic-euglycemic clamp procedure progressively increased with progressive 
weight loss and the accompanying increase in insulin sensitivity, demonstrating that the 
impairment in postprandial lactate production associated with obesity is corrected by weight 
loss. However, we are not able to determine which tissues were responsible for the weight-
loss induced increase in lactate production during the clamp procedure, which could involve 
any of the insulin-sensitive tissues that produce lactate, such as skeletal muscle, adipose 
tissue, liver, intestine, and kidney.
It is possible that the relationship we observed between [LAC] and insulin resistance 
represents an adverse effect of lactate on insulin action. Data from studies conducted in 
rodent models demonstrate that hyperlactemia affects cellular insulin signaling and impairs 
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insulin-stimulated glucose uptake in skeletal muscle (6, 7, 8). However, these findings have 
not been confirmed in human subjects; experimental sodium lactate infusion, in conjunction 
with sodium hydroxide infusion to prevent lactic acidosis, did not have adverse effects on 
glucose disposal or insulin sensitivity in healthy lean people (32, 33). The reason for the 
discrepancy between studies in rodents and people is not clear, but it is possible the changes 
in plasma pH and [LAC] achieved during lactate infusion in people were not adequate to 
affect insulin action. Additional studies are needed to determine whether [LAC] is involved 
in the pathogenesis of insulin resistance in people with obesity.
This study demonstrates the inter-relationships among weight loss, hepatic and muscle 
glucose kinetics, insulin sensitivity, and [LAC] in people with obesity, and suggests fasting 
[LAC] can serve as an additional biomarker of glucose-related insulin resistance. Additional 
studies are needed to identify the precise mechanisms responsible for relationship between 
[LAC] and insulin action and to clarify the importance of circulating lactate in the 
pathogenesis of insulin resistance in people.
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IMPORTANCE OF THE STUDY
What is already known about this subject?
• Lactate is an intermediate of glucose metabolism that has been implicated in 
the pathogenesis of insulin resistance and type 2 diabetes.
• People with obesity and diabetes have higher fasting plasma lactate 
concentration ([LAC]) compared with people who are lean and healthy.
What does your study add?
• This study demonstrates that fasting [LAC] is positively associated with the 
rate of endogenous glucose production, and negatively associated with insulin 
sensitivity, assessed as the relative increase in glucose disposal during a 
hyperinsulinemic-euglycemic clamp procedure.
• Progressive (5% through 16%) weight loss caused a progressive decrease in 
fasting [LAC], whereas the relative decrease in fasting [LAC] in response to 
5% weight loss was directly correlated with the relative decrease in 
endogenous glucose production and the relative increase in insulin-stimulated 
glucose disposal.
• Fasting [LAC] is a potential biomarker of insulin resistance with respect to 
glucose metabolism.
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Figure 1. CONSORT diagram of the study
Flow of participants through screening procedures, baseline testing, randomization into 
weight loss and weight maintenance, and post-intervention testing. Adopted from ref. (10).
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Figure 2. Interrelationship between plasma lactate concentration ([LAC]) and glucose kinetics
(A) Relationship between fasting [LAC] and the glucose rate of appearance (Ra) into 
plasma. (B) Relationship between fasting [LAC] and the relative increase in glucose rate of 
disappearance (Rd) during a hyperinsulinemic-euglycemic clamp procedure. (C) 
Relationship between the relative change in [LAC] and the relative increase in glucose Rd 
during a hyperinsulinemic-euglycemic clamp procedure.
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Figure 3. Effect of moderate (5%) weight loss on plasma lactate concentration ([LAC]) during 
postabsorptive conditions and a hyperinsulinemic-euglycemic clamp procedure
(A) Fasting [LAC] before and after weight maintenance and 5% weight loss. *Value 
significantly different from corresponding weight maintenance value, interaction p=0.009 
evaluated by using two-way repeated measures ANOVA. (B) Change in [LAC] induced by a 
hyperinsulinemic-euglycemic clamp procedure before and after weight maintenance and 5% 
weight loss. **Value different from corresponding weight maintenance value, interaction 
p=0.06 evaluated by using one-way repeated measures ANOVA. (C) Relationship between 
the relative change in fasting [LAC]pl with the relative change in glucose rate of appearance 
(Ra). (D) Relationship between the relative change in fasting [LAC] with the relative change 
in insulin sensitivity [assessed as the percent increase in glucose rate of disappearance 
during a hyperinsulinemic-euglycemic clamp procedure].
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Figure 4. Effect of progressive weight loss on plasma lactate concentration ([LAC])
(A) Fasting [LAC] before and after progressive weight loss (evaluated by using one-way 
repeated measures ANOVA, p=0.002; linear effect of time, p=0.006). (B) Change in [LAC] 
during a hyperinsulinemic-euglycemic clamp procedure before and after progressive weight 
loss (evaluated by using one-way repeated measures ANOVA, p=0.016; linear effect of time, 
p=0.006). *Value significantly different from Pre value, p <0.05.
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